Braveheart Bio Q2 EPS $(2.51)
Benzinga Newsdesk 1 month ago
NewsEarningsEarnings Misses
Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of $(0.14) per share
Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of $(0.14) per share from the same period last year.